Novel immunomodulatory peptides in respiratory inflammation and beyond
Our lead programme focuses on upstream inhibition of TLR4-mediated inflammatory cascades, for over-the-board anti-inflammatory properties.
A receptor-specific and pathway-agnostic drug holds significant potential in multiple inflammatory diseases, where TLR4 plays a pivotal role at the onset of the disease as well as in preventing its resolution.
In-vitro data confirms the anti-inflammatory nature of our peptide’s action, as well as its ability to block both IFN-1 and NF-KB pathways.
In-vivo data in acute lung inflammation models in mice exhibits reduced secretion of pro-inflammatory cytokines and upregulation of pro-inflammatory cytokines.
Furthermore, our peptide’s stability and lack of toxicity has been evidenced, making it perfectly suitable for use as an API.
Development Pipeline
Management
Hadrien Lanvin, MSc, CEO
Anna Kostrzak, PhD, Head of R&D
Directors
Rémi Gloeckler, PhD
Hadrien Lanvin, MSc, CEO
Philippe Rousseau, MSc
Bruno Tocque, PhD
Partners Network
Supported by
Inquiries at contact@evorabio.com
© EVORA Biosciences 2024